## Nina A Hering

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2275436/publications.pdf

Version: 2024-02-01

687363 839539 18 759 13 18 citations h-index g-index papers 19 19 19 1395 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Effect of Revascularization on Intramuscular Vascular Endothelial Growth Factor Levels in Peripheral Arterial Disease. Biomedicines, 2022, 10, 471.	3.2	1
2	Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ER $\hat{l}^2$ and IL-6/gp130/STAT3 signaling. Cellular Oncology (Dordrecht), 2021, 44, 167-177.	4.4	16
3	The Punicalagin Metabolites Ellagic Acid and Urolithin A Exert Different Strengthening and Anti-Inflammatory Effects on Tight Junction-Mediated Intestinal Barrier Function In Vitro. Frontiers in Pharmacology, 2021, 12, 610164.	3.5	24
4	Increased proinflammatory cytokines in mesenteric fat in major surgery and Crohn's disease. Surgery, 2021, 169, 1328-1332.	1.9	4
5	Effect of bowel preparation on intestinal permeability and inflammatory response during postoperative ileus in mice. Surgery, 2021, 170, 1442-1447.	1.9	1
6	Blockage of Cholinergic Signaling via Muscarinic Acetylcholine Receptor 3 Inhibits Tumor Growth in Human Colorectal Adenocarcinoma. Cancers, 2021, 13, 3220.	3.7	12
7	Contribution of the Cpx envelope stress system to metabolism and virulence regulation in Salmonella enterica serovar Typhimurium. PLoS ONE, 2019, 14, e0211584.	2.5	19
8	Tilivalline- and Tilimycin-Independent Effects of Klebsiella oxytoca on Tight Junction-Mediated Intestinal Barrier Impairment. International Journal of Molecular Sciences, 2019, 20, 5595.	4.1	19
9	Epithelial barrier dysfunction as permissive pathomechanism in human intestinal graft-versus-host disease. Bone Marrow Transplantation, 2018, 53, 1083-1086.	2.4	2
10	Lactoferrin protects against intestinal inflammation and bacteriaâ€induced barrier dysfunction ⟨i⟩in vitro⟨ i⟩. Annals of the New York Academy of Sciences, 2017, 1405, 177-188.	3.8	60
11	Myrrh exerts barrier-stabilising and -protective effects in HT-29/B6 and Caco-2 intestinal epithelial cells. International Journal of Colorectal Disease, 2017, 32, 623-634.	2.2	19
12	<i>Yersinia enterocolitica</i> Affects Intestinal Barrier Function in the Colon. Journal of Infectious Diseases, 2016, 213, 1157-1162.	4.0	13
13	A Transgenic Probiotic Secreting a Parasite Immunomodulator for Site-Directed Treatment of Gut Inflammation. Molecular Therapy, 2014, 22, 1730-1740.	8.2	63
14	Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. Journal of Physiology, 2012, 590, 1035-1044.	2.9	210
15	Oral and Fecal Campylobacter concisus Strains Perturb Barrier Function by Apoptosis Induction in HT-29/B6 Intestinal Epithelial Cells. PLoS ONE, 2011, 6, e23858.	2.5	70
16	Yersinia enterocolitica induces epithelial barrier dysfunction through regional tight junction changes in colonic HT-29/B6 cell monolayers. Laboratory Investigation, 2011, 91, 310-324.	3.7	35
17	Transforming Growth Factor-β, a Whey Protein Component, Strengthens the Intestinal Barrier by Upregulating Claudin-4 in HT-29/B6 Cells1,2. Journal of Nutrition, 2011, 141, 783-789.	2.9	90
18	Therapeutic Options to Modulate Barrier Defects in Inflammatory Bowel Disease. Digestive Diseases, 2009, 27, 450-454.	1.9	101